Concord Biotech · NSE: CONCORDBIO · BSE: 543960
Q2 FY24 results · Jul–Sep 2023
Concord Biotech reported revenue from operations of ₹262.35 crore and net profit of ₹81.02 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 262.35 | — | — | 194.83 | +34.7% |
| Other income | 8.13 | — | — | 6.65 | +22.1% |
| Total income | 270.47 | — | — | 201.48 | +34.2% |
| Profit before share of associates & JVs and tax | 113.18 | — | — | 65.01 | +74.1% |
| Share of profit/(loss) of associates & JVs | (3.47) | — | 6.02 | ||
| Net profit for the period | 81.02 | — | — | 54.49 | +48.7% |
| EPS, basic (₹) | 7.74 | — | — | 5.21 | +48.6% |
| Net margin (%) | 30.9 | — | 28.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 262.35 | — | — | 194.83 | +34.7% |
| Other income | 8.13 | — | — | 6.65 | +22.1% |
| Total income | 270.47 | — | — | 201.48 | +34.2% |
| Profit before tax | 113.18 | — | — | 65.01 | +74.1% |
| Net profit for the period | 84.49 | — | — | 48.47 | +74.3% |
| EPS, basic (₹) | 8.08 | — | — | 4.63 | +74.4% |
| Net margin (%) | 32.2 | — | 24.9 |
Consolidated
- Filed with BSE
- 22 Nov 2023, 14:07 IST
- Board meeting
- 08 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Nov 2023, 14:07 IST
- Board meeting
- 08 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE